Clinical Trials Logo

Down Syndrome (DS) clinical trials

View clinical trials related to Down Syndrome (DS).

Filter by:
  • None
  • Page 1

NCT ID: NCT01699711 Completed - Down Syndrome (DS) Clinical Trials

Normalization of dyrk1A and APP Function as an Approach to Improve Cognitive Performance and Decelerate AD Progression in DS Subjects: Epigallocatechin Gallate as Therapeutic Tool

Start date: February 2012
Phase: Phase 2
Study type: Interventional

Epigallocatechin-3-gallate (EGCG), the major catechin in green tea, is postulated to modulate dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) and amyloid beta precursor protein (APP) gene overexpression in the brains of Down syndrome mouse models. The clinical study is aimed at demonstrating that normalization of Dyrk1A and APP functions is a therapeutic approach to improve cognitive performance and decelerate AD (Alzheimer's disease) like progression.